Demonstration of Epstein-Barr Virus DNA in Acetowhite Lesions of the Vulva

1994 ◽  
Vol 5 (1) ◽  
pp. 25-28 ◽  
Author(s):  
E Voog ◽  
A Ricksten ◽  
G B Löwhagen ◽  
A Ternesten
Keyword(s):  
Human Papilloma Virus ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Papilloma Virus ◽  
Hpv Dna ◽  
Barr Virus ◽  
Oral Hairy Leukoplakia ◽  
Hairy Leukoplakia ◽  
Ebv Dna ◽  
Epstein Barr

Acetowhite lesions in the vulva disclosing koilocytosis have been related to infection by human papilloma virus (HPV). Because of the clinical resemblance of these lesions to oral hairy leukoplakia (OHL), and EBV-manifestation, 23 women with acetowhite koilocytotic lesions in the vulva were examined. The PCR-technique was used to detect EBV DNA as well as HPV DNA in 17% of 23 patients examined. In a control group of 19 patients EBV DNA was detected in 11% and HPV DNA in 42% of cell samples from normal vulvar mucosa. EBV DNA has not previously been demonstrated in the vulvar mucosa, and this virus might be related to subclinical acetowhite lesions.

Are acetowhite lesions of the cervix correlated to the presence of Epstein-Barr virus DNA?

1997 ◽  
Vol 8 (7) ◽  
pp. 432-436 ◽  
Author(s):  
Ewa Voog ◽  
Anne Ricksten ◽  
Monica Stenglein ◽  
Fredrik Jonassen ◽  
Annika Ternesten ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Predictive Factor ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Study Group ◽  
Hpv Dna ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

The purpose of this study was to investigate whether Epstein-Barr virus (EBV) is associated with acetowhite lesions of the portio cervix, demonstrating koilocytosis and/or cervical intraepithelial neoplasia (CIN) I-III. The study group comprised 37 women admitted to the Department of Gynaecology and Obstetrics, Sahlgrenska University Hospital, Go teborg because of pathological colposcopy or cytology of the portio cervix. Colposcopically, all exhibited acetowhite lesions of the portio cervix. Cells were sampled with a cytobrush for examination for EBV and human papillomavirus (HPV) DNA by polymerase chain reaction (PCR) and a biopsy was taken for histopathology. Biopsies from 5 patients positive for EBV by PCR in cervical cell samples were examined by an in situ hybridization technique for EBER (Epstein-Barr virus encoded RNA), RNAs expressed in latent EBV infection. The control group consisted of women attending the Department of Dermato-Venereology at the same hospital for STD check-up. These had a normal cytology and no signs of acetowhiteness of the portio cervix. In the study group, EBV DNA was found in 30% and HPV DNA in 51%. In the control group 57% exhibited EBV DNA and 23% HPV DNA. EBV was not found to be a predictive factor in the development of koilocytosis and/or CIN I-III. HPV was a predictive factor in acetowhite, koilocytotic lesions. No expression of EBER was found in the 5 biopsies examined by in situ hybridization.

scholarly journals Epstein-Barr virus in oral hairy leukoplakia scrapes: identification by PCR

2005 ◽  
Vol 19 (4) ◽  
pp. 317-321 ◽  
Author(s):  
Tatiana Lucianelli Komatsu ◽  
Elena Riet Correa Rivero ◽  
Marina Helena Cury Gallottini de Magalhães ◽  
Fabio Daumas Nunes
Keyword(s):  
Epstein Barr Virus ◽  
Clinical Evidence ◽  
Hiv Positive ◽  
Control Group ◽  
Barr Virus ◽  
Oral Hairy Leukoplakia ◽  
Hairy Leukoplakia ◽  
History Of ◽  
Epstein Barr ◽  
The Moment

Oral hairy leukoplakia (OHL) is a lesion associated with a compromised immune system, and its diagnosis is determined by the demonstration of the presence of Epstein-Barr virus (EBV) in lesional tissue. The purpose of this article was to develop a simple technique to help the diagnosis of OHL, using PCR as an alternative technique to evidence EBV in scrapings. DNA samples were obtained by scraping the lateral border of the tongue of 38 adult patients: 29 HIV-positive patients (4 with clinical evidence of OHL; 4 with history of OHL, but without lesion at the moment the samples were collected; and 21 without clinical evidence of OHL), and 9 healthy volunteers for the control group. DNA was extracted from scrapes and amplified by PCR using specific primers for EBV. Of the 29 cases of HIV-positive patients, 22 (75.86%) were positive for EBV: 2 patients with clinical evidence of OHL, 4 patients with history of OHL, but without lesion at the moment the samples were collected, and 16 patients without clinical evidence of OHL. In the control group, samples of 5 (55.56%) healthy volunteers presented amplification for EBV. We concluded that the use of PCR in oral scrapes suggests a high sensitivity but low specificity for the diagnosis of OHL.

Frequency of Epstein–Barr virus and human papilloma virus in patients with nasopharyngeal carcinoma

2020 ◽  
Vol 277 (7) ◽  
pp. 2041-2047
Author(s):  
Ilhan Altekin ◽  
Abdullah Taş ◽  
Omer Yalcin ◽  
Selis Gulseven Guven ◽  
Zülkar Aslan ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Human Papilloma Virus ◽  
Epstein Barr Virus ◽  
Papilloma Virus ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Persistence and Transition of Epstein‐Barr Virus Genotypes in the Pathogenesis of Oral Hairy Leukoplakia

2004 ◽  
Vol 190 (2) ◽  
pp. 387-395 ◽  
Author(s):  
Dennis M. Walling ◽  
Wiguins Etienne ◽  
Autumn J. Ray ◽  
Catherine M. Flaitz ◽  
C. Mark Nichols
Keyword(s):  
Epstein Barr Virus ◽  
Barr Virus ◽  
Oral Hairy Leukoplakia ◽  
Hairy Leukoplakia ◽  
Virus Genotypes ◽  
Epstein Barr

scholarly journals HLA-Mismatched GPBSCs infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A observational study from a single center

2020 ◽  
Author(s):  
Yue Song ◽  
Jingshi Wang ◽  
Yini Wang ◽  
Zhao Wang
Keyword(s):  
Survival Rate ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Median Survival Time ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Short Term ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Better Than

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory state. Epstein–Barr virus (EBV) infection associated HLH (EBV-HLH) is one of the most common secondary HLH and suffers a very poor prognosis. Allo-HSCT is often required for refractory EBV-HLH, but some patients still cannot proceed to the next allo-HSCT due to various factors. This study aimed to observe the efficacy of HLA-mismatched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (GPBSCs) infusion for refractory EBV-HLH. Methods: A retrospective case-control study of refractory EBV-HLH patients with GPBSCs infusion from HLA-mismatched donors after chemotherapy (as GPBSCs group) and sole chemotherapy (as control group) was performed. Efficacy was evaluated 2 and 4 weeks and all patients were followed up until 1 March 2018.Results: There were 18 cases who accepted infusion between March 2016 and Sep 2017 and 19 were randomly selected from refractory EBV-HLH patients who underwent salvage therapy during the same period for the control group. In GPBSCs group, WBC (p=0.017), Fbg (p=0.040), ferritin (p=0.039) improved significantly after treatment. The overall response rate was 66.7% (CR 22.2%, PR 44.4%). However, there is no significant differences in changes of WBC, HGB, PLT, TG, Fbg, Ferritin, AST, ALT, T-bil between two groups. Only the Fbg level was recovered better in the GPBSCs infusion group (p=0.003). In the GPBSCs group, EBV-DNA decreased significantly after 2 weeks (p=0.001) and 4 weeks (p=0.012) after treatment, and the effect of the decrease was significantly better than that of the chemotherapy alone group in 2 weeks but not 4 weeks (p2w=0.011, p4w=0.145). The median survival time in the infusion group was 20.4 weeks [95%CI 10.9, 29.9], and the median survival time in the control group was 10.8 weeks [95%CI 0-24.34]. In the short-term, the infusion group’s survival rate was better (2-month 88.89% vs. 52.63%, p=0.008; 3-month 83.33% vs. 47.09%, p=0.012), but there was no difference in OS (p=0.287). Conclusions: Infusing GPBSCs combined with chemotherapy is effective, especially in decreasing EBV-DNA, performs better than chemotherapy alone, and improve short term survival rate. GPBSCs infusion is suggested as a bridging treatment method to allo-HSCT.

scholarly journals HLA-Mismatched GPBSCs infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A observational study from a single center

2020 ◽  
Author(s):  
Yue Song ◽  
Jingshi Wang ◽  
Yini Wang ◽  
Zhao Wang
Keyword(s):  
Survival Rate ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Median Survival Time ◽  
Epstein Barr Virus ◽  
Control Group ◽  
Short Term ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Better Than

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory state. Epstein–Barr virus (EBV) infection associated HLH (EBV-HLH) is one of the most common secondary HLH and suffers a very poor prognosis. Allo-HSCT is often required for refractory EBV-HLH, but some patients still cannot proceed to the next allo-HSCT due to various factors. This study aimed to observe the efficacy of HLA-mismatched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (GPBSCs) infusion for refractory EBV-HLH. Methods: A retrospective case-control study of refractory EBV-HLH patients with GPBSCs infusion from HLA-mismatched donors after chemotherapy (as GPBSCs group) and sole chemotherapy (as control group) was performed. Efficacy was evaluated 2 and 4 weeks and all patients were followed up until 1 March 2018. Results: There were 18 cases who accepted infusion between March 2016 and Sep 2017 and 19 were randomly selected from refractory EBV-HLH patients who underwent salvage therapy during the same period for the control group. In GPBSCs group, WBC (p=0.017), Fbg (p=0.040), ferritin (p=0.039) improved significantly after treatment. The overall response rate was 66.7% (CR 22.2%, PR 44.4%). However, there is no significant differences in changes of WBC, HGB, PLT, TG, Fbg, Ferritin, AST, ALT, T-bil between two groups. Only the Fbg level was recovered better in the GPBSCs infusion group (p=0.003). In the GPBSCs group, EBV-DNA decreased significantly after 2 weeks (p=0.001) and 4 weeks (p=0.012) after treatment, and the effect of the decrease was significantly better than that of the chemotherapy alone group in 2 weeks but not 4 weeks (p2w=0.011, p4w=0.145). The median survival time in the infusion group was 20.4 weeks [95%CI 10.9, 29.9], and the median survival time in the control group was 10.8 weeks [95%CI 0-24.34]. In the short-term, the infusion group’s survival rate was better (2-month 88.89% vs. 52.63%, p=0.008; 3-month 83.33% vs. 47.09%, p=0.012), but there was no difference in OS (p=0.287). Conclusions: Infusing GPBSCs combined with chemotherapy is effective, especially in decreasing EBV-DNA, performs better than chemotherapy alone, and improve short term survival rate. GPBSCs infusion is suggested as a bridging treatment method to allo-HSCT.

Sign in / Sign up

Export Citation Format

Share Document